Positive Quality Interventions Highlight Appropriate Drug Therapy

PQIs promote higher quality patient care through increased speed to therapy, reduced cost and hospitalization and by improving persistence and adherence.

The treatment and management of oncology patients on oral drug therapy is continually changing and evolving. Professionals at in-office dispensing practices are in a unique position to ensure proper treatment, increase compliance and maximize outcomes. Positive Quality Interventions (PQIs), an NCODA Quality Standard, are designed to operationalize and standardize those practices to achieve these positive clinical outcomes.

SEARCH PQIs

Abemaciclib Appropriate Patient Identification

Written by: Jan Montgomery, PharmD, South Carolina Oncology Associates and Jacob Dygert, South University School of Pharmacy

DOWNLOAD HERE

 

Chemotherapy Induced Diarrhea

Written by: Joshua Nubla, PharmD, NCODA

DOWNLOAD HERE


CLL and Del17P

Written by: Danny Olszta, PharmD, BCOP, Jolliet Oncology Hematology Associates 

DOWNLOAD HERE


Drug Induced Hand‐Foot Syndrome

Written by: Jonas Congelli, RPh, Hematology Oncology Associates of CNY 

DOWNLOAD HERE


EGFR Inhibitors

Written by: Danny Olszta, PharmD, BCOP, Jolliet Oncology Hematology Associates

DOWNLOAD HERE

 

Management of Abemaciclib Associated Diarrhea

Written by: Derek Gyori, PharmD and Julianne Orr, PharmD

DOWNLOAD HERE


Managing Myelofibrosis Patients

Written by: Todd Murphree, PharmD, Clearview Cancer Institute

DOWNLOAD HERE


MCRC Regorafenib Updated

Written by: Neal Dave, PharmD, Texas Oncology; Natasha Khrystolubova, RPh, BCOP, Florida Cancer Specialists 

DOWNLOAD HERE


MCRC ‐ Trifluridine and Tipiracil

Written by: Jennifer M. Hasiak O’Doherty, PharmD, Hematology Oncology Consultants, PC

DOWNLOAD HERE

Neratinib Diarrhea Management

Written by: Eric Dallara, RPh, New England Cancer Specialists

DOWNLOAD HERE

Niraparib Dose Adjustment

Written by: Michelle Phillips, PharmD, University of Rochester Medical Center

DOWNLOAD HERE

NSCLC Afatinib Management

Written by: Chris Sellers, RPh, Texas Oncology

DOWNLOAD HERE


Olanzapine Use in Chemotherapy Induced Nausea and Vomiting (CINV)

Written by: Julianne Orr, PharmD, Indiana University Health Simon Cancer Center

DOWNLOAD HERE


Polycythemia Vera

Written by: Neal Dave, PharmD, Texas Oncology 

DOWNLOAD HERE

Regorafenib in the treatment of Hepatocellular Carcinoma

Written by: Jody Agena, PharmD, Virginia Cancer Specialists

DOWNLOAD HERE


Stomatitis

Written by: Matthew Schulz, RPh Rocky Mountain Cancer Centers

DOWNLOAD HERE


Venetoclax Dispensing Procedure

Written by: Todd Murphree, PharmD, Clearview Cancer Institute

DOWNLOAD HERE

PQI CORPORATE SPONSORS

NCODA recognizes our PQI corporate sponsors who demonstrate their continued commitment and support to helping NCODA members through this beneficial educational platform

PQI Submissions

PQ’Is are created and written by NCODA members to provide interventions that increase the speed to therapy, reduce costs and hospitalizations, improve persistence and adherence, and provide a higher level of quality patient care.

Neal Dave, PharmD, Chair – Texas Oncology, TX
Julianne Orr, PharmD, BCOP, Chair – Indiana University Health, Simon Cancer Center, IN
Howard Cohen, BS, PharmD, MS, FASHP, Chair-Elect – Smilow Cancer Hospital/Yale New Haven Health, CT
Chara Reid-Reed, PharmD – Dupage Medical Group, IL
Darrell Willyard, PharmD – OCSRI, OK
Gina Wertz, PharmD – Nebraska Hematology Oncology, NE
Jen Hasiak O’Doherty, PharmD – Hematology & Oncology Consultants Pharmacy
Jody Agena, PharmD, MBA, BCOP – Virginia Cancer Specialists, VA
Kirollos Hanna, PharmD, BCPS, BCOP – University of Minnesota Medical Center & Mayo Clinic, MN
Lawrence Garbo, MD – New York Oncology Hematology, NY
Marie Sirek, PharmD – Billings Clinic, MT
Margaret McGuinness, PharmD, BCOP – Compass Oncology, OR
Natasha Heimbigner, PharmD – Summit Cancer Centers, WA
Yen Nguyen, PharmD – Oncology Consultants, PA, TX
Important Notice: National Community Oncology Dispensing Association, Inc. (NCODA), has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.